GSK on NicoWater
This article was originally published in The Tan Sheet
Executive Summary
Nicorette and Nicoderm marketer "urges FDA to advise QT5 that it must immediately cease distribution and marketing" of its nicotine-containing beverage NicoWater as an OTC homeopathic product in recent comments. Claims in radio advertising and labeling that NicoWater "relieves the symptoms of tobacco cravings" render the product an unapproved new drug, the letter states. GSK also laments that FDA's failure to take action against the product has allowed QT5 to arrange for NicoWater to be sold through Rite Aid and Eckerd stores, and made it easier for consumers to purchase the product over the Internet. The comments follow a citizen petition objecting to the sale of NicoWater as an OTC homeopathic product, filed by the NRT marketer in March (1"The Tan Sheet" April 7, 2003, p. 7)...
You may also be interested in...
Nicowater OTC Homeopathic Remedy Classification Illegal – GSK
QT5's Nicowater nicotine beverage cannot legally be marketed as an over-the-counter homeopathic product because it contains "too great a concentration of nicotine," GSK asserts in a March 21 1citizen petition filed by Washington, D.C. law firm Ropes & Gray
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.